Oncology Nursing News
NDA Filed for Avutometinib Plus Defactinib for Low-Grade Serous Ovarian Cancer. By Chris Ryan. November 3rd 2024. The FDA has received a rolling new drug application (NDA) for avutometinib plus defactinib for the treatment of adult patients with recurrent low-grade serous ovarian cancer harboring KRAS mutations who have received at least 1 ...
Know Your Ports - Oncology Nursing News
Dec 21, 2017 · A port is typically placed on the right side of the patient’s chest and about 3 to 5 fingerbreadths below the clavicle. The insertion scar provides a useful landmark, because the port is usually located 0.5 to 1 inch below the surgical incision. Bringing a patient who has large amounts of breast tissue to a fully upright position, with the ...
What Are Professional Boundaries and Why Do They Matter?
Oct 4, 2017 · The National Council of State Boards of Nursing defines a boundary crossing as a “brief excursion across professional lines of behavior.”. Your action may be unplanned and honestly intended to meet a patient’s or a caregiver’s need. Consider the following: It seems like a harmless, kind gesture. But questions to ask yourself are: 1.
DART Releases New Guidelines on Radiation-Based Treatments for …
Aug 29, 2024 · New clinical guidelines have been published by the Dermatology Association of Radiation Therapy (DART) on noninvasive, radiation-based treatments for basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), according to a news release by DART. 1 To assist dermatologists, radiation oncologists, and radiation therapists in appropriate treatment use, the new guidelines for the treatment of ...
Opinion: The Media May Have Oversold AOH1996, City of Hope's …
Sep 20, 2023 · Opinion: The Media May Have Oversold AOH1996, City of Hope's Pioneering Cancer Drug. AOH1996, a drug named in honor of Anna Olivia Healy, is being tested in a phase 1 trial. As nurses, we must help our patients understand that phase 1 trials represent very early research. Early-phase clinical trials often involve medications that have not yet ...
Understanding Why Black Women Have Denser Breasts May Help …
Apr 21, 2015 · Since the fibroglandular tissue appears as white on the mammogram, it makes it difficult to visually detect breast cancers. Research has shown that women who have the highest breast density have a 4 to 6 times greater risk for breast cancer compared with women with lower breast density. Although several studies have previously shown that black ...
Six Ways Nurses Can Advocate for Patients - Oncology Nursing …
Aug 30, 2018 · Six Ways Nurses Can Advocate for Patients. August 30, 2018. By Alene Nitzky, PhD, RN, OCN. Article. This is the first in a 3-part series about nurses as advocates within healthcare. Many nurses think of advocacy as the most important role we play in patient care. We need to remember that to best serve patients, we must have our own house in order.
Chlorhexidine Dressings Decrease Risk for Infection in Patients …
Sep 25, 2024 · Chlorhexidine dressings, along with proper patient education, are key in preventing central line-associated blood stream infections in patients with cancer. Chlorhexidine-impregnated dressings or sponges—as well as patient education—can reduce the rate of central line-associated blood stream infection (CLABSI) in patients with cancer ...
Understanding the Role of an Oncology Research Nurse
Sep 26, 2024 · An oncology research nurse balances patient care with rigorous data collection, emphasizing communication and collaboration to advance cancer research. Oncology research nurses play an integral role in collecting data and assessing for adverse events throughout a clinical trial, which, in turn, can lead to their support in the development of ...
Olaparib Without ADT May Elicit High Response Rates in Prostate …
Sep 24, 2024 · Olaparib (Lynparza) monotherapy contributed to high and durable responses, defined as a 50% or greater decline in prostate specific antigen (PSA), in patients with high-risk biochemically recurrent prostate cancer after radical prostatectomy, as demonstrated by findings published in JAMA Oncology.. In this phase 2, multicenter, single-arm, nonrandomized-controlled trial, olaparib presented a ...